

IN THE CLAIMS

Please AMEND the claims as follows:

1-18. (Cancel)

19. (New) A fusion polypeptide, comprising

a. a peptide of 3 to 30 amino acids capable of selectively binding said fusion polypeptide to tumor vessel endothelial cells; and

b. a tissue factor or a fragment thereof capable of activating blood clotting when said fusion polypeptide binds to tumor vessel endothelial cells,
wherein said peptide of 3 to 30 amino acids is coupled directly or via a linker having up to 15 amino acids to the C-terminus of said tissue factor or fragment thereof.

20. (New) The fusion polypeptide according to claim 19, wherein said coupling is via a linker having up to 15 amino acids.

21. (New) The fusion polypeptide according to claim 19, wherein said coupling is direct.

22. (New) The fusion polypeptide according to claim 19, wherein said tissue factor or a fragment thereof has the sequence shown in SEQ ID NO: 1.

23. (New) The fusion polypeptide according to claim 19, wherein in said tissue factor or a fragment thereof has the sequence shown in SEQ ID NO: 2.

24. (New) The fusion polypeptide according to claim 19, wherein said peptide of 3 to 30 amino acids has a linear or cyclic structure.

25. (New) The fusion polypeptide according to claim 19, wherein said peptide of 3 to 30 amino acids comprises the amino acid sequence RGD or NGR.

26. (New) The fusion polypeptide according to claim 25, wherein said peptide of 3 to 30 amino acids is selected from the group consisting of GRGDSP (SEQ ID NO: 33) and

GNGRAHA (SEQ ID NO: 34).

27. (New) The fusion polypeptide according to claim 25, wherein said peptide of 3 to 30 amino acids is selected from the group consisting of GCNGRCG (SEQ ID NO:36), GCNGRCVSGCAGRC (SEQ ID NO:37), GCVLNGRMECT (SEQ ID NO:38), and GALNGRSHAG (SEQ ID NO:35).

28. (New) The fusion polypeptide according to claim 19, wherein said fusion polypeptide has the sequence selected from the group consisting of SEQ ID NOs: 3-8.

29. (New) A nucleic acid encoding a fusion polypeptide according to claim 19.

30. (New) The nucleic acid according to claim 29, wherein said fusion polypeptide has the sequence selected from the group consisting of SEQ ID NOs: 10-15.

31. (New) A vector comprising a nucleic acid according to claim 29.

32. (New) A cell comprising a nucleic acid according to claim 29.

33. (New) A cell comprising a vector according to claim 31.

34. (New) A pharmaceutical composition comprising a fusion polypeptide according to claim 19.

35. (New) A pharmaceutical composition comprising a nucleic acid according to claim 29.

36. (New) A pharmaceutical composition comprising a vector according to claim 31.

37. (New) A pharmaceutical composition comprising a cell according to claim 32.

38. (New) The pharmaceutical composition according to claim 34, further comprising one or more pharmaceutical carrier(s), excipient(s), and/or adjuvant(s).

39. (New) A method of treating a patient with a neoplastic disease using a pharmaceutical

composition according to claim 34.

40. (New) The method according to claim 39, wherein said neoplastic disease is selected from the group consisting of bronchial carcinomas and other tumors of the thorax and mediastinum, breast cancers and other gynecological tumors, colorectal carcinomas, pancreatic carcinomas and other tumors of the gastrointestinal tract, malignant melanomas and other tumors of the skin, tumors in the head and neck region, prostate cancers and other urogenital tumors, sarcomas, endocrine-active tumors, leukemias and Myelodysplastic Syndromes and Hodgkin lymphomas and non-Hodgkin lymphomas.